Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
British Journal of Haematology|August 22, 2025
When is it time to bid farewell to anticoagulation?Julia Czuprynska, Roopen AryaBritish Journal of Haematology|August 3, 2019
Annotation: travel and thrombosisJulia Czuprynska, Roopen AryaBritish Journal of Haematology|October 15, 2014
The prevention of pregnancy-related venous thromboembolismBoriana Guimicheva, Julia Czuprynska, Roopen AryaBritish Journal of Haematology|June 3, 2017
Current challenges and future prospects in oral anticoagulant therapyJulia Czuprynska, Jignesh P Patel, Roopen AryaEuropean Journal of Gastroenterology & Hepatology|March 26, 2016
Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysisSameer Zaman, Stefan Wiebe, William Bernal, et al.Brain, Behavior, and Immunity|April 15, 2021
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK casesPuja R Mehta, Sean Apap Mangion, Matthew Benger, et al.Journal of Thrombosis and Thrombolysis|June 7, 2019
What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trialZara Sayar, Julia Czuprynska, Jignesh P Patel, et al.Blood|August 4, 2020
Postdischarge venous thromboembolism following hospital admission with COVID-19Lara N Roberts, Martin B Whyte, Loizos Georgiou, et al.Thrombosis Research|August 24, 2024
Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysisRachel E Clapham, Victoria Speed, Rosalind Byrne, et al.Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysisVictoria Speed, Bruce Green, Lara N Roberts, et al.Pageof 1